TY - JOUR
T1 - Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD)
T2 - A Report of an International Research Collaboration Network
AU - Pavlik, Valory N.
AU - Burnham, Samantha C.
AU - Kass, Joseph S.
AU - Helmer, Catherine
AU - Palmqvist, Sebastian
AU - Vassilaki, Maria
AU - Dartigues, Jean François
AU - Hansson, Oskar
AU - Masters, Colin L.
AU - Pérès, Karine
AU - Petersen, Ronald C.
AU - Stomrud, Erik
AU - Butler, Lesley
AU - Coloma, Preciosa M.
AU - Teitsma, Xavier M.
AU - Doody, Rachelle
AU - Sano, Mary
N1 - Funding Information:
Core funding for the AIBL study was pro vided by the CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF) in partnership with the CRC for Mental Health, Edith Cowan University, Mental Health Research institute, Dementia Australia, National Ageing Research Institute, Austin Health, Macquarie University, CogState Ltd, Hollywood Private Hospital, and Sir Charles Gairdner Hospital. The study also received funding from the National Health and Medical Research Council (NHMRC), Dementia Collaborative Research Centres program, and McCusker Alzheimer’s Research Foundation, and operational infrastructure support from the Government of Victoria.
Funding Information:
The Baylor cohort has been supported by NIH P50 AG08664, the Texas Alzheimer’s Research and Care Consortium, and the Effie Marie Cain endowment.
Funding Information:
AMI was funded by AGRICA (CAMARCA, CRCCA, CCPMA PREVOYANCE, CPCEA, AGRI PREVOYANCE), la Mutualité Sociale Agricole (MSA) de Gironde, la Caisse Centrale de la Mutu-alité Sociale Agricole (CCMSA), Caisse Nationale de Solidarité pour l’Autonomie (CNSA) and SCOR Insurance (France). The neur-imaging AMImage1 and AMImage2 projects were funded by the Programme Hospitalier de Recherche Clinique - PHRC 2008 (Sponsor’s code CHUBX 2008/13) and PHRC 2011 (Sponsor’s code CHUBX 2011/15).
Funding Information:
The Three-City study is conducted under a partnership agreement between the Institut National de la Santé et de la Recherche Médicale (INSERM), the University Bordeaux 2 Victor Segalen and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The Three-City study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, Institut de la Longévité, Conseils Régionaux d’Aquitaine et Bourgogne, Fondation de France, Ministry of Research-INSERM Programme “Cohortes et collections de données biologiques”, Agence Nationale de la Recherche ANR PNRA 2006 and LongVie 2007, the “Fondation Plan Alzheimer” (FCS 2009–2012), the Caisse Nationale de Solidarité pour l’Autonomie (CNSA) and Roche.
Funding Information:
BioFINDER-1: Work at the authors’ research center was supported by the Swedish Research Council, the Knut and Alice Wallenberg foundation, the Marianne and Marcus Wallenberg foundation, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, the Swedish Alzheimer Foundation, and the Swedish Brain Foundation.
Funding Information:
The CONCORD-AD collaboration network is funded by F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Funding Information:
MCSA was supported by the NIH (U01 AG006786, P50 AG016574, P30 AG062677, R37 AG011378, R01 AG041851, R01 NS097495), the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Clinic, the Liston Award, the Schuler Foundation, the GHR Foundation, and the Mayo Foundation for Medical Education and Research; and was made possible by the Rochester Epidemiology Project (R01 AG034676).
Funding Information:
PAQUID was supported by AGRICA, ARMA (Bordeaux); Caisse Nationale d’Assurance Mal-adie des Travailleurs Salariés (CNAMTS); Caisse Nationale de Solidarité pour l’Autonomie (CNSA); Conseil Général de la Dordogne; Conseil Général de la Gironde; Conseil Régional d’Aquitaine; Fondation de France; France Alzheimer (Paris); GIS Longévité; Institut National de la Santé et de la Recherche Médicale (INSERM); IPSEN France; Mutuelle Générale de l’Éducation Nationale (MGEN); Mutu-alité Sociale Agricole (MSA); Novartis Pharma (France); and SCOR Insurance (France). Institut de recherche en santé publique (IReSP), Association France Alzheimer.
Publisher Copyright:
© 2022 - The authors. Published by IOS Press.
PY - 2022
Y1 - 2022
N2 - Longitudinal observational cohort studies are being conducted worldwide to understand cognition, biomarkers, and the health of the aging population better. Cross-cohort comparisons and networks of registries in Alzheimer's disease (AD) foster scientific exchange, generate insights, and contribute to the evolving clinical science in AD. A scientific working group was convened with invited investigators from established cohort studies in AD, in order to form a research collaboration network as a resource to address important research questions. The Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD) collaboration network was created to bring together global resources and expertise, to generate insights and improve understanding of the natural history of AD, to inform design of clinical trials in all disease stages, and to plan for optimal patient access to disease-modifying therapies once they become available. The network brings together expertise and data insights from 7 cohorts across Australia, Europe, and North America. Notably, the network includes populations recruited through memory clinics as well as population-based cohorts, representing observations from individuals across the AD spectrum. This report aims to introduce the CONCORD-AD network, providing an overview of the cohorts involved, reporting the common assessments used, and describing the key characteristics of the cohort populations. Cohort study designs and baseline population characteristics are compared, and available cognitive, functional, and neuropsychiatric symptom data, as well as the frequency of biomarker assessments, are summarized. Finally, the challenges and opportunities of cross-cohort studies in AD are discussed.
AB - Longitudinal observational cohort studies are being conducted worldwide to understand cognition, biomarkers, and the health of the aging population better. Cross-cohort comparisons and networks of registries in Alzheimer's disease (AD) foster scientific exchange, generate insights, and contribute to the evolving clinical science in AD. A scientific working group was convened with invited investigators from established cohort studies in AD, in order to form a research collaboration network as a resource to address important research questions. The Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD) collaboration network was created to bring together global resources and expertise, to generate insights and improve understanding of the natural history of AD, to inform design of clinical trials in all disease stages, and to plan for optimal patient access to disease-modifying therapies once they become available. The network brings together expertise and data insights from 7 cohorts across Australia, Europe, and North America. Notably, the network includes populations recruited through memory clinics as well as population-based cohorts, representing observations from individuals across the AD spectrum. This report aims to introduce the CONCORD-AD network, providing an overview of the cohorts involved, reporting the common assessments used, and describing the key characteristics of the cohort populations. Cohort study designs and baseline population characteristics are compared, and available cognitive, functional, and neuropsychiatric symptom data, as well as the frequency of biomarker assessments, are summarized. Finally, the challenges and opportunities of cross-cohort studies in AD are discussed.
KW - Alzheimer's disease
KW - CONCORD-AD network
KW - biomarkers
KW - cognitive function
KW - cohort
KW - dementia
KW - observational study
KW - population characteristics
UR - http://www.scopus.com/inward/record.url?scp=85122786461&partnerID=8YFLogxK
U2 - 10.3233/jad-210525
DO - 10.3233/jad-210525
M3 - Review article
C2 - 34776434
AN - SCOPUS:85122786461
SN - 1387-2877
VL - 85
SP - 31
EP - 45
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
IS - 1
ER -